Pilot study demonstrates N-Succinyl-S-farnesyl-L-cysteine reduces erythema and inflammatory lesions in rosacea subjects

J Cosmet Dermatol. 2023 Sep;22(9):2622-2623. doi: 10.1111/jocd.15758. Epub 2023 Apr 18.

Authors

Eduardo Pérez¹, José R Fernández¹, Corey Fitzgerald¹, Karl Rouzard¹, Jason Healy¹, Masanori Tamura¹, Michael Voronkov¹, Jeffry B Stock², Maxwell Stock¹

Affiliations

¹ Signum Biosciences, 202, Monmouth, New Jersey, USA.
² Department of Molecular Biology, Princeton University, Princeton, New Jersey, USA.

PMID: 37073424
DOI: 10.1111/jocd.15758

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Cysteine*
Erythema / drug therapy
Humans
Pilot Projects
Rosacea* / drug therapy
Treatment Outcome

Substances

Cysteine

Grants and funding

Signum Biosciences